Yeztugo (lenacapavir), a revolutionary twice-yearly injectable for HIV pre-exposure prophylaxis (PrEP), has been approved, offering a significant advancement in AIDS prevention.

The FDA has approved Yeztugo (lenacapavir), a groundbreaking twice-yearly injectable for HIV pre-exposure prophylaxis (PrEP), marking a significant advancement in HIV prevention strategies.

A Game-Changer for HIV Prevention

Traditional PrEP requires daily pills, which can be challenging for many people to maintain consistently. Lenacapavir changes this paradigm:

Just two injections per year
Over 99% effective at preventing HIV
Eliminates daily adherence challenges
Discreet prevention option

How It Works

Lenacapavir is a capsid inhibitor that works differently from other HIV medications:

Blocks multiple stages of the HIV lifecycle
Remains active in the body for six months
Provides consistent protection without daily action
Works for both prevention and treatment

Clinical Trial Results

The SUNLENCA trials demonstrated remarkable results:

Zero HIV infections among participants receiving lenacapavir
Significantly better protection than daily oral PrEP
Well-tolerated with manageable side effects
High participant satisfaction

Who Can Benefit

This option may be especially valuable for:

People who struggle with daily medication
Those in high-risk situations
Individuals seeking privacy in prevention
Anyone looking for convenient protection

Addressing HIV Stigma

Twice-yearly dosing helps reduce stigma by:

Eliminating visible daily pills
Reducing pharmacy visits
Providing discreet protection
Normalizing preventive care

Access and Availability

Important considerations:

Requires healthcare visits twice yearly
Insurance coverage expanding
Patient assistance programs available
Roll-out continuing through 2026

The Road to Ending HIV

This approval represents a major step toward ending the HIV epidemic, making prevention more accessible and achievable for millions at risk.

Twice-Yearly HIV Prevention Injection Approved by FDA